1. Home
  2. NAMS vs APAM Comparison

NAMS vs APAM Comparison

Compare NAMS & APAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • APAM
  • Stock Information
  • Founded
  • NAMS 2019
  • APAM 1994
  • Country
  • NAMS Netherlands
  • APAM United States
  • Employees
  • NAMS N/A
  • APAM N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • APAM Investment Managers
  • Sector
  • NAMS Health Care
  • APAM Finance
  • Exchange
  • NAMS Nasdaq
  • APAM Nasdaq
  • Market Cap
  • NAMS 3.1B
  • APAM 3.0B
  • IPO Year
  • NAMS N/A
  • APAM 2013
  • Fundamental
  • Price
  • NAMS $35.94
  • APAM $43.06
  • Analyst Decision
  • NAMS Strong Buy
  • APAM Hold
  • Analyst Count
  • NAMS 10
  • APAM 5
  • Target Price
  • NAMS $43.70
  • APAM $46.00
  • AVG Volume (30 Days)
  • NAMS 1.3M
  • APAM 406.8K
  • Earning Date
  • NAMS 11-06-2025
  • APAM 10-28-2025
  • Dividend Yield
  • NAMS N/A
  • APAM 8.33%
  • EPS Growth
  • NAMS N/A
  • APAM 2.75
  • EPS
  • NAMS N/A
  • APAM 3.71
  • Revenue
  • NAMS $64,006,000.00
  • APAM $1,158,202,000.00
  • Revenue This Year
  • NAMS N/A
  • APAM $8.29
  • Revenue Next Year
  • NAMS N/A
  • APAM $8.55
  • P/E Ratio
  • NAMS N/A
  • APAM $11.75
  • Revenue Growth
  • NAMS 762.15
  • APAM 8.88
  • 52 Week Low
  • NAMS $14.06
  • APAM $32.75
  • 52 Week High
  • NAMS $41.47
  • APAM $49.54
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 59.08
  • APAM 42.94
  • Support Level
  • NAMS $35.50
  • APAM $43.02
  • Resistance Level
  • NAMS $36.81
  • APAM $45.35
  • Average True Range (ATR)
  • NAMS 2.26
  • APAM 0.95
  • MACD
  • NAMS -0.42
  • APAM 0.06
  • Stochastic Oscillator
  • NAMS 22.49
  • APAM 18.21

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.

Share on Social Networks: